{"organizations": [], "uuid": "e5c8d8424fa529acb48a79d2e0f24436206dbd39", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180118.html", "section_title": "Archive News &amp; Video for Thursday, 18 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-caladrius-biosciences-announces-co/brief-caladrius-biosciences-announces-completion-of-enrollment-of-phase-2-t-rex-clinical-trial-of-clbs03-for-type-1-diabetes-idUSASB0C1EH", "country": "US", "domain_rank": 408, "title": "BRIEF-Caladrius Biosciences Announces Completion Of Enrollment Of Phase 2 T-Rex Clinical Trial Of CLBS03 For Type 1 Diabetes", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.553, "site_type": "news", "published": "2018-01-18T21:06:00.000+02:00", "replies_count": 0, "uuid": "e5c8d8424fa529acb48a79d2e0f24436206dbd39"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-caladrius-biosciences-announces-co/brief-caladrius-biosciences-announces-completion-of-enrollment-of-phase-2-t-rex-clinical-trial-of-clbs03-for-type-1-diabetes-idUSASB0C1EH", "ord_in_thread": 0, "title": "BRIEF-Caladrius Biosciences Announces Completion Of Enrollment Of Phase 2 T-Rex Clinical Trial Of CLBS03 For Type 1 Diabetes", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "caladrius biosciences inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 18 (Reuters) - Caladrius Biosciences Inc:\n* CALADRIUS BIOSCIENCES ANNOUNCES COMPLETION OF ENROLLMENT OF PHASE 2 T-REX CLINICAL TRIAL OF CLBS03 FOR TYPE 1 DIABETES\n* CALADRIUS BIOSCIENCES INC - TOPLINE DATA FROM PRIMARY ENDPOINT OF COMPLETED STUDY ON CLBS03 EXPECTED IN EARLY 2019 Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-18T21:06:00.000+02:00", "crawled": "2018-01-19T12:18:41.012+02:00", "highlightTitle": ""}